Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures

Published:2018-04-12 Issue:11 Volume:124 Page:2355-2364
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Spigel David R.¹²,Burris Howard A.¹²,Greco F. Anthony¹²,Shih Kent C.¹²,Gian Victor G.¹²,Lipman Andrew J.¹³,Daniel Davey B.¹⁴,Waterhouse David M.⁵,Finney Lindsey¹,Heymach John V.⁶,Hainsworth John D.¹²^ORCID

Affiliation:

1. Sarah Cannon Research Institute; Nashville Tennessee

2. Tennessee Oncology; Nashville Tennessee

3. Florida Cancer Specialists; Naples Florida

4. Tennessee Oncology; Chattanooga Tennessee

5. Oncology Hematology Care, Inc; Cincinnati Ohio

6. The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

National Institutes of Health

GlaxoSmithKline

Genzyme

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin.,2015

2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol.,2000

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med.,2005

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med.,2006

5. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer;Spigel;J Clin Oncol.,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

2. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Cancers;2024-03-18

3. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma;Bioscience Reports;2022-08

4. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China;Frontiers in Pharmacology;2022-03-16

5. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials;Translational Lung Cancer Research;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3